Clinical Trial Update: Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial update for lentiviral gene transfer as a treatment for X-linked severe combined immunodeficiency in children over 2 years old.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Severe Combined Immunodeficiency

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: X-Linked Combined Immunodeficiency Diseases | Phase 1, Phase 2 | Status: UNKNOWN